AI funding and infrastructure shift; cure trials quietly grow

Today the cure pipeline stays large—21,374 global active cure-related trials—while the information layer around the AI-capital transition keeps moving fast. In the last 24 hours there were 14 new wire signals and 10 new cure research updates, but the most consequential pattern is the systems shift: Replit reportedly switched its default model from Anthropic to OpenAI, while markets signaled a short window for capital to reroute as AI valuations get punished by inflation-driven rotation. On the cure side, researchers advanced tools for measurement and prediction—benzodiazole-based quantitative imaging probes, new benchmarking for subcellular perturbation prediction, multiplex microarrays for antibody cross-reactivity, and even a caution that ambient RNA correction can confound doublet detection. If you’re trying to convert today’s volatility into momentum for biology, prioritize rigorous, quantitative readouts and benchmarked prediction pipelines—because that’s what turns the next funding and compute shift into faster, safer discovery. The window is still open.